Latest Conference Articles

February 9th 2021, 7:45pm

Transplantation and Cellular Therapy Meetings

February 9, 2021 - Patients with refractory large B-cell lymphoma have less to gain from axicabtagene ciloleucel if they have never achieved a complete response to any line of prior therapy.

February 9th 2021, 7:42pm

Transplantation and Cellular Therapy Meetings

February 9, 2021 - Ruxolitinib, when administered using a pediatric dosing algorithm, was found to elicit responses in patients with chronic graft-versus-host disease with acceptable safety.

February 9th 2021, 2:56pm

Transplantation and Cellular Therapy Meetings

February 9, 2021 - JSP191 in combination with low-dose total body irradiation and fludarabine has demonstrated efficacy and tolerability in older patients with minimal residual disease–positive acute myeloid leukemia and myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

February 9th 2021, 12:30am

Transplantation and Cellular Therapy Meetings

February 8, 2021 — Narsoplimab demonstrated clinical activity and a favorable survival benefit in patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy, according to updated results of a pivotal phase 2 trial.

February 8th 2021, 11:10pm

PER® Winter Lung Cancer Conference

With the emergence of multiple immunotherapy approaches in recent years, the decision of whether to use a single agent, to pair it with chemotherapy, or to pair it with another immunotherapy agent has come to the forefront of treatment.

February 8th 2021, 10:44pm

PER® Winter Lung Cancer Conference

Julie R. Brahmer, MD, discusses factors to consider when determining when to initiate immunotherapy in a patient with newly diagnosed non–small cell lung cancer.

February 8th 2021, 10:41pm

PER® Winter Lung Cancer Conference

Luis E. Raez, MD, discusses the potential utility of cemiplimab-rwlc in non–small cell lung cancer.

February 8th 2021, 9:38pm

PER® Winter Lung Cancer Conference

Vincent Lam, MD, describes frontline indications for this patient population, as well as strategies that can be utilized to overcome TKI resistance in later lines of therapy.

February 8th 2021, 7:45pm

Transplantation and Cellular Therapy Meetings

February 8, 2021 - Prior exposure to anti-CD19 therapy did not impact response to the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

February 8th 2021, 5:32pm

Transplantation and Cellular Therapy Meetings

February 8, 2021 - These findings may have implications for patients with hematologic malignancies, suggesting the development of protective memory against SARS-CoV2 and non-SARS human coronaviruses.

February 7th 2021, 9:00pm

PER® Winter Lung Cancer Conference

Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients.

February 7th 2021, 7:25pm

PER® Winter Lung Cancer Conference

Synergizing EGFR TKIs with antiangiogenic agents and chemotherapy, as well as improving the use of molecular classification, are novel strategies aimed at taking the frontline setting for patients with EGFR-mutant non–small cell lung cancer to the next level.

February 7th 2021, 5:25pm

PER® Winter Lung Cancer Conference

Mark A. Socinski, MD, discusses the nuances of the PACIFIC trial and ongoing research with durvalumab that could extend the reach of immunotherapy in early-stage lung cancer.

February 6th 2021, 7:15pm

PER® Winter Lung Cancer Conference

Over the past 2 decades, the field of EGFR-mutated non–small cell lung cancer has grown tremendously, but the influx of data and the recent regulatory approval of adjuvant osimertinib have raised several important questions to be addressed to ensure that the optimal treatment approach is utilized.

February 6th 2021, 6:30pm

PER® Winter Lung Cancer Conference

Rogerio C. Lilenbaum, MD, discusses some of the key clinical issues facing the lung cancer field, the role of genomic testing and multidisciplinary care, and the challenges that arose with telemedicine during the coronavirus disease 2019 pandemic.

February 6th 2021, 5:55pm

PER® Winter Lung Cancer Conference

In the quest for scientific purity, one should not lose sight of the meaningful end points that can make a difference in patients’ daily lives.

February 6th 2021, 5:00pm

PER® Winter Lung Cancer Conference

Mary Jo J. Fidler, MD, discusses the potential utility of circulating tumor DNA to inform treatment escalation in lung cancer.

February 6th 2021, 5:00pm

PER® Winter Lung Cancer Conference

Rogerio C. Lilenbaum, MD, discusses the challenges of integrating telehealth services in lung cancer.

February 6th 2021, 12:00am

PER® Winter Lung Cancer Conference

Mark A. Socinski, MD, discusses the role of immunotherapy in PD-L1–negative lung cancer.

February 6th 2021, 12:00am

PER® Winter Lung Cancer Conference

Hossein Borghaei, DO, MS, discusses selecting between single-agent versus combination therapies in lung cancer.